You are here: Home > Prescription(RX) Drugs > F > Ferrex 28 (Breckenridge Pharmaceutical, Inc.)|
ascorbic acid, folic acid, cyanocobalamin, iron, ferrous fumurate and succinic acid
Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.
Ferrex™ 28 Tablets for oral administration to provide 28-day iron supplement therapy.
Each maroon film-coated tablet contains:
Inactive Ingredients: Citric Acid, Croscarmellose Sodium, Crospovidone, Dicalcium Phosphate, FD&C Blue No. 1 Lake, FD&C Red No. 40 Lake, FD&C Yellow No. 6 Lake1, Hypromellose, Magnesium Silicate, Magnesium Stearate, Microcrystalline Cellulose, Mineral Oil, Pharmaceutical Glaze, Polyethylene Glycol, Polyvinylpyrrolidone, Silica, Sodium Lauryl Sulfate, Soy Polysaccharide, Stearic Acid and Titanium Dioxide.
Allergen: Contains Soy.
Each blue film-coated tablet contains:
Inactive Ingredients: Croscarmellose Sodium, Crospovidone, Dicalcium Phosphate, FD&C Blue No. 1 Lake, Hypromellose, Magnesium Silicate, Magnesium Stearate, Microcrystalline Cellulose, Mineral Oil, Silica, Soy Polysaccharide, Stearic Acid, Titanium Dioxide and Triacetin.
Allergen: Contains Soy.
INDICATIONS AND USAGE
For the nutritional supplementation of anemias responsive to oral iron, such as hypochromic anemia associated with pregnancy, chronic or acute blood loss, dietary restriction, metabolic disease and post-surgical convalescence.
This product is contraindicated in patients with a known hypersensitivity to any of the ingredients. Hemochromatosis and hemosiderosis are contraindications to iron supplementation.
Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where vitamin B12 is deficient.
Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children. In case of accidental overdose, call a doctor or poison control center immediately.
Do not exceed recommended dose.
The type of anemia and the underlying cause or causes should be determined before taking Ferrex™ 28 Tablets. Since the anemia may be a result of a systemic disturbance, such as recurrent blood loss, the underlying cause or causes should be corrected, if possible.
Folic acid in doses above 0.1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations remain progressive. Pernicious anemia should be excluded before using this product since folic acid may mask the symptoms of pernicious anemia.
Clinical studies on this product have not been performed in subjects aged 65 and over to determine whether elderly subjects respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug supplementation.
Adverse reactions with iron supplementation may include constipation, diarrhea, nausea, vomiting, dark stools and abdominal pain. Adverse reactions with iron supplementation are usually transient.
Allergic sensitization has been reported following both oral and parenteral administration of folic acid.
The clinical course of acute iron overdosage can be variable. Initial symptoms may include abdominal pain, nausea, vomiting, diarrhea, tarry stools, melena, hematemesis, hypotension, tachycardia, metabolic acidosis, hyperglycemia, dehydration, drowsiness, pallor, cyanosis, lassitude, seizures, shock and coma.
DOSAGE AND ADMINISTRATION
Usual adult dose is 1 tablet daily, or as directed by a physician. Ferrex™ 28 supplies a 28 day course of iron supplementation that consists of 21 maroon active tablets and 7 blue absorption period tablets. Take 1 maroon tablet daily for 21 days, followed by 1 blue tablet daily for 7 days. After 28 tablets have been taken, a new course may be started if prescribed.
Ferrex™ 28 Tablets are available as 21 maroon active tablets debossed "B 586" and 7 blue absorption period tablets debossed "B 587". Supplied in packages of 28 tablets each containing 4 child-resistant blisters of 7 tablets. NDC 51991-588-28.
KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. IN CASE OF ACCIDENTAL OVERDOSE, SEEK PROFESSIONAL ASSISTANCE OR CONTACT A POISON CONTROL CENTER IMMEDIATELY.
All prescription substitutions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product.
PRINCIPAL DISPLAY PANEL - Carton
Revised: 01/2011 Breckenridge Pharmaceutical, Inc.
Reproduced with permission of U.S. National Library of Medicine
Copyright © 2019
|Over-the-counter (OTC) Drugs|